Silexion Therapeutics (NASDAQ:SLXN) Announces Earnings Results

Silexion Therapeutics (NASDAQ:SLXN) posted its quarterly earnings results on Friday. The company reported ($5.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($21.20) by $16.03, FiscalAI reports.

Silexion Therapeutics Stock Performance

NASDAQ:SLXN traded down $0.04 on Friday, reaching $0.42. The stock had a trading volume of 1,001,454 shares, compared to its average volume of 492,483. Silexion Therapeutics has a 12-month low of $0.37 and a 12-month high of $80.00. The company has a 50-day moving average of $2.42 and a 200 day moving average of $8.52.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Maxim Group lowered shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.